Thus, the aim of the present study was to describe the positioning trends of targeted therapies for IBD since 2015 (when the first non-anti-TNF biological agent became available in Spain), and to identify factors (related to IBD or external) that may influence the choice between different options. This evidence concerns the gene TNF and inflammatory bowel disease.